Neuroinflammation and Myelin Status in Alzheimer’s Disease, Parkinson’s Disease, and Normal Aging Brains: A Small Sample Study

Fei Han, Richard J. Perrin, Qing Wang, Yong Wang, Joel S. Perlmutter, John C. Morris, Tammie L. S. Benzinger, and Jinbin Xu

1Department of Radiology, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
2Department of Pathology & Immunology, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
3Knight Alzheimer Disease Research Center, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
4Department of Neurology, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
5Department of Neuroscience, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
6Department of Physical Therapy, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA
7Department of Occupational Therapy, Washington University School of Medicine, 510 S, Kingshighway Blvd, St. Louis, MO 63110, USA

Correspondence should be addressed to Jinbin Xu; jinbinxu@wustl.edu

Received 2 April 2019; Revised 6 June 2019; Accepted 12 June 2019; Published 4 July 2019

1.Introduction

White matter disease is a common pathology involved in the dementia of Alzheimer’s disease [1, 2], multiple sclerosis [3], and cerebrovascular disease [4]. Brain white matter is generally categorized into two types: deep and superficial white matter. Compared with deep white matter, superficial white matter undergoes later myelination and has less wraps around the axon. These features render it vulnerable to aging- or injury-related impairment [5]. Moreover,
superficial white matter has complex connectivity with cortical fibers and contributes to information processing and integration [6]. This disorder of superficial white matter has been implicated in cognitive dysfunction, such as Alzheimer’s disease, schizophrenia, and Huntington’s disease [7]. Astrocytes are the most numerous cell type in the CNS and perform many physiological functions in this system. These functions include maintaining homeostasis at the synapse, regulation of neuronal signaling, protecting neurons from oxidative damage, and assisting in the formation of myelin. Astrocytes not only control proliferation and migration of oligodendrocytes but also regulate the timing of myelination [8]. Some studies suggest that GFAP knockout mice have more extensive dysfunction in the white matter than in the gray matter, indicating that astrocytes play crucial roles in facilitating and maintaining normal myelination [9]. However, overactivated astrocytes also secrete factors associated with the inhibition of myelination, such as transforming growth factor (TGF-α) and bone morphogenetic protein (BMP) 2/4 [10].

In addition, cerebral amyloid-beta (Aβ), neurofilibrillary tangles (abnormal tau), and neuroinflammation are all involved in AD pathology [11]. Dysfunctional perivascular cells also play a pathological role in neurodegenerative diseases and cerebral vascular diseases [12]. In the current study, we examined 15 autopsied human brains that included 5 cases of Parkinson disease (PD), 6 cases of Alzheimer disease (AD), and 4 cases of age-matched cognitively normal controls (NC) using immunohistochemistry (IHC) staining for GFAP and Iba1, Aβ and phosphorylated tau, and α-SMA, as well as myelin and axon staining. We found that cases with high GFAP expression (4 AD, 3 PD, and 1 NC) in superficial white matter have a significantly negative correlation with myelin loss, whereas cases with low GFAP expression (2AD, 2 PD, and 3 NC) do not present negative correlation. Phosphorylated tau was highly expressed and increased with age in AD, and tau burden was significantly higher than Aβ in AD cases. These data suggest that chronic inflammation-induced astrocytosis in superficial white matter might be associated with myelin impairment and disease progression in these patients. Furthermore, it suggests that tau is a more potent biomarker than Aβ for aging-associated dementia in AD.

2. Materials and Methods

2.1. Cases. Postmortem human brain tissue samples including six AD, five PD, and four age-matched cognitively healthy controls (3 female and 12 male) were obtained from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center (AD and control cases) and the Movement Disease Research Center (PD cases), Department of Neurology, Washington University School of Medicine (Table 1). Written consent from the participant or the next-of-kin was obtained for brain removal, following local Institutional Review Board policies and procedures at Washington University in St. Louis.

2.2. Tissue Collection, Staining, and Immunohistochemistry. Briefly, brains were removed at the time of autopsy and the left hemispheres were fixed in 10% neutral-buffered formalin for 2 weeks or more before samples were processed for histology and embedded in paraffin. Histologic sections were cut at 6 μm thickness and mounted on glass slides. Histologic stains included hematoxylin and eosin, Luxol fast blue and Cresyl echt violet (NeuronMyelinStain), and Bielschowsky silver staining (Hitobiotech Corp. Kingsport, TN, USA). For immunohistochemistry, all specimens underwent heat-induced antigen retrieval (0.01 M citrate buffer at pH 6.0) and were immunostained by the EnVision method. Specimens were then incubated overnight at 4°C with rabbit monoclonal anti-GFAP antibody (1:250 dilution, Abcam Inc. MA, USA), rabbit polyclonal anti-Iba1 antibody (1:250 dilution, Wako Chemicals USA, Inc), and rabbit polyclonal to alpha smooth muscle actin antibody (1:100 dilution, Abcam Inc. MA, USA). Avidin-biotin complex (VECTASTAIN® UNIVERSAL ELITE ABC KIT) was used for immunohistochemical staining of Aβ (10D5, Elan Pharmaceuticals, San Francisco, CA, USA) and phosphorylated tau (PHF-1, generous gift of Dr. Peter Davies, Feinstein Institute for Medical Research, Manhasset, NY, USA), phosphorylated TDP-43 (Cosmo Bio USA Inc, Carlsbad, CA, USA), phosphorylated α-synuclein (Wako Chemicals USA Inc, Richmond, VA, USA), and PBS without the primary antibody for a negative control. Specimens were then incubated with horseradish peroxidase-linked goat anti-rabbit or mouse secondary antibody and ABC complex, followed by reaction with diaminobenzidine. No specific immunostaining was detected in negative controls under these conditions. The positive staining for GFAP and Iba1 was located in the cytoplasm, and their positive areas and densities of myelin and axon were analyzed by VISIOPHARM imaging analytic software. The severity of Lewy body pathology was assessed using the Braak et al.’s Parkinson’s disease staging scale [13]. Alzheimer’s disease neuropathological changes were assessed by the Braak staging method [14, 15].

2.3. Statistical Analysis. All values are expressed as mean ± SEM. Mann–Whitney nonparametric test and one-way analysis of variance (ANOVA) were used to identify significant differences in two or multiple comparisons. Pearson correlation coefficients and two-tailed hypothesis test were used to evaluate correlation between two variables. All analyses were performed by GraphPad Prism software. A level of p < 0.05 was considered statistically significant.

3. Results

3.1. Clinical Features of 15 Cases. As shown in Table 1, there are 6 cases of AD, 5 cases of PD, and 4 cases of age-matched neurologically normal controls, with the median age of 78 (69–93) years including 3 females and 12 males. There are no significant difference in the average age at death (p > 0.8, Student’s t-test), postmortem interval (p > 0.19,
3.3. Different Functional States of Microglia Were Observed in AD, PD, and NC Samples. Compared to cognitive intact healthy control, more dystrophic and activated microglia were spotted in AD and PD patients. These findings suggest not only the activation but also the underlying degenerative process of microglia contribute to pathogenesis of AD and PD (Figure 3).

3.4. Negative Correlation between the GFAP Expression and Myelin Density in the Superficial White Matter of Astrocytosis Group (4 AD, 3 PD, and 1 NC). After classifying these cases into two groups based on expression of GFAP in superficial white matter, the astrocytosis group which has high GFAP expression and includes 4 AD, 3 PD, and 1 NC cases and the nonastrocytosis group which includes 2 PD, 2 AD, and 3 NC cases. Representative images of AD, PD, and NC patients for GFAP, Iba1, and myelin and axonal staining are shown in Figures 4(a) and 4(c). As shown in Figures 4(b) and 4(d), the expression of GFAP significantly inversely correlates with myelin densities of superficial white matter in the astrocytosis group ($R^2 = 0.78$, $p = 0.003$), but GFAP expression does not correlate with myelin densities of superficial white matter in the nonastrocytosis group ($R^2 = 0.32$, $p = 0.18$). However, as shown in Figure 5(a), the expression of GFAP does not significantly correlate with axon density in the astrocytosis group ($R^2 = 0.0007$, $p = 0.35$) nor in the nonastrocytosis group ($R^2 = 0.33$, $p = 0.18$), which suggest that astrocyte may also contribute axon generation in white matter. Although a high but not significant expression of Iba1 was detected in the astrocytosis group compared to the nonastrocytosis group, the expression status of Iba1 does not correlate with myelin or axon densities whether in the astrocytosis group or the nonastrocytosis group (Figures 5(c)–5(f)).

The expression of GFAP and Iba1 in different regions of 6 cases of AD, 5 cases of PD, and 4 cases of age-matched cognitively intact controls.

We also analyzed the expression of GFAP and Iba1 in superficial white matter, cortical gray matter, and striatum in these patients (6 AD, 5 PD, and 4 NC). As shown in Figures 6(a)–6(h), there is no significant differences in expression of GFAP and Iba1 in AD, PD, and NC groups in different regions ($p > 0.05$), probably due to small sample limitation. Furthermore, we analyzed myelin and axon status in superficial white matter, there is no significant differences except mild decline of myelin sheath observed in PD patients.

3.5. Tauopathy and Pericyte Status in 6 Cases of AD, 5 Cases of PD, and 4 Cases of Age-Matched Cognitively Intact Controls. Hyperphosphorylated tau was identified by labeling with a PHF mouse monoclonal antibody, and tau was found to be
extensively expressed in all six AD cases. Tau was not, or rarely, expressed in PD and NC cases. The positive areas of tau in AD cases were primarily localized in the gray matter and junction between gray and white matter. Intracellular tau expression was found to be localized in the cytoplasm of neurons and gliocytes. Phosphorylated tau was highly expressed in AD cases. We classified these cases into two age groups (under 80 and over 80). Tau expression was observed to be significantly higher in the >80 group than in the <80 group (Figure 7). Amyloid beta (Aβ) was labeled by a 10D5 antibody, and Aβ plaque burden was found to be significantly lower than tau in these AD cases (Figure 7). Dysfunction of perivascular cells was also reported to be involved in the neuropathological diseases, such as Alzheimer’s disease and multiple sclerosis. Here, we investigated pericytes status by labeling α-SMA, a specific marker for pericytes. No perivascular cytopathology was identified in these cases (Figure 8). However, we cannot exclude the presence of perivascular cytopathology in other brain regions due to our sample limitations.

4. Discussion

Chronic neuroinflammation, mediated by reactive astrocytes and activated microglia, plays an important role in the progression of neurodegenerative diseases, such as
Figure 2: Astrocytes and microglia in the striatal tissue sections using GFAP and Iba1 antibodies. (a) Representative images of activated astrocytes and microglia in white matter, gray matter, and striatum. The activated astrocytes showed enlarged cell bodies and elongated fibers, while activated microglia showed meatball-like appearance with enlarged cell bodies and shortened processes. The scale bar represents 100 μm. (b, c) The quantitative analysis of the GFAP and Iba1 expression in white matter in the astrocytosis and the non-astrocytosis groups. The bars represent mean ± SEM. *represents $p < 0.05$.

Figure 3: Continued.
Figure 3: Different morphologies of microglia in AD, PD, and NC. (a, b) Dystrophic microglia from striatal white matter and cortex of two AD patients which displayed twisted or fragmented processes and cell body enlargement. (c, d) Activated and dystrophic microglia from striatum of two PD patients which showed cell body enlargement and fragmented processes. (e, f) Resting microglia from striatum of two health controls which showed the small cell body with highly branched processes. The scale represents 400 μm.

Figure 4: Continued.
Figure 4: GFAP, Iba1, myelin, and axon staining and correlation analysis between GFAP expression and myelin density. Left panel shows the representative IHC images of GFAP, Iba1, myelin, and axon staining in the striatal tissue sections from AD, PD, and NC cases in the astrocytosis (a) and the nonastrocytosis group (c). Right panel shows the correlation between GFAP expression and myelin density in the astrocytosis (b) and the nonastrocytosis (d) groups.

Figure 5: Continued.
Figure 5: Correlation analysis between GFAP and Iba1 staining with axon and myelin densities. (a, b) The correlation between the expression of GFAP and axon densities in the astrocytosis and nonastrocytosis group. (c, d) The correlation between the expression of Iba1 and myelin densities in the astrocytosis and nonastrocytosis group. (e, f) The correlation between the expression of Iba1 and axon densities in the astrocytosis and nonastrocytosis group.

Figure 6: Continued.
Figure 6: Relative GFAP and Iba1 expression and myelin and axon status in PD, AD, and age-matched cognitive intact controls (NC). (a) Expression of GFAP in the striatum. (b) Expression of GFAP in white matter. (c) Expression of GFAP in gray matter. (d) Expression of Iba1 in the striatum. (e) Expression of Iba1 in white matter. (f) Expression of Iba1 in gray matter. (g) Myelin status in AD, PD, and NC. (h) Axon status in AD, PD, and NC. The bars represent mean ± SEM.

Figure 7: Continued.
Parkinson’s disease and Alzheimer’s disease. In this study, we assessed neuroinflammation in the striatum and associated cortical gray matter and white matter from 15 postmortem human brains including 6 cases of AD, 5 cases of PD, and 4 neurologically intact age-matched controls. Although our data suggest that there is a trend...
that AD cases (with high burden of beta amyloid and tau) have more neuroinflammation than PD and control cases, we found no significant differences for activation and proliferation of astrocytes and microglia either in cortical gray matter, superficial white matter, or striatum among PD, AD, and controls. This is consistent with translocator protein binding (TSPO) or previous peripheral benzodiazepine receptor (PBR) quantitative autoradiography studies using $^{[3]}$HPK11195 and $^{[3]}$HPBR28 in post-mortem frozen human brains; TSPO binding density was found to be not significantly different among AD ($n = 7$), dementia with Lewy bodies (DLB) disease ($n = 5$), or cognitively intact age-matched controls ($n = 8$) in these brain regions [16]. However, some cases in the current study (4 AD, 3 PD, and 1 NC) showed a significantly higher expression of GFAP in the superficial white matter (>0.5 positive staining area), in comparison to the other cases (2 AD, 2 PD, and 3 NC) (<0.4 positive staining area).

Based on this difference, we classified these cases into two groups: astrocytosis (4 AD, 3 PD, and 1 NC) and non-astrocytosis (2 AD, 2 PD, and 3 NC). Staining of myelin and axon was performed to investigate the relationships between the activation of glia cells (astrocyte and microglia) and neurodegeneration, as reflected by axonal and myelin integrity in the subcortical-striatal superficial white matter. We found that GFAP expression significantly negatively correlated with myelin density in superficial white matter in the astrocytosis group, but not in the nonastrocytosis group. In contrast, Iba1 staining did not correlate significantly with myelin density in either group.

Myelin sheath can boost neural transduction via the node of Ranvier by insulating nerve cell axons in the central and peripheral nervous systems. Damaged myelin sheath could be a biomarker for the early-stage axon degeneration. It has been reported that demyelination could induce axon abnormalities by reducing axon caliber, abnormal neurofilament distribution, and increasing mitochondria number [17–19]. However, a study posited that axonal degeneration could occur independently from myelin loss [20]. Here, we also investigated axon density in superficial white matter and evaluated its association with the expression of GFAP or Iba1 and myelin densities in superficial white matter. Myelin density did not significantly correlate with axon density in all 15 cases (data not shown), nor did axon density significantly correlate with GFAP or Iba1 expression.

Tau pathology has been a hallmark of Alzheimer’s diseases (AD). Tau exists as monomers, paired helical filaments (PHFs), and straight filaments in AD [21]. Here, we investigated tau status by labeling with a PHF antibody in the striatal sections of AD, PD, and NC cases. Phosphorylated tau was highly expressed in all AD patients, especially in the age >80 group, compared to PD and NC cases. Furthermore, we also conducted amyloid beta immunohistochemistry in the adjacent sections of all cases. No concurrent expression of phosphorylated tau and amyloid beta was found in these cases except for one case, 83-year-old female. This case had a decent expression of amyloid beta in the gray matter area. The overall expression of amyloid beta was significantly lower compared to phosphorylated tau in all AD cases. No obvious expression of amyloid beta was observed in all PD and NC cases. These data support the hypothesis that tau pathology is independent of amyloid beta in the neurodegenerative diseases and that neurofibrillary tangles (tauopathy) are a better biomarker for predicting cognitive impairment in Alzheimer’s diseases.

Pericytes, the perivascular-specialized smooth muscle cells, have multiple pathological functions in the brain. Interactions between pericytes and endothelial cells are important for the remodeling and maintenance of the vascular system. Pericytes also regulate the neurotransmitter transport and vascular permeability. Dysfunction of pericytes is involved in neuropathological diseases, such as hypertension, diabetic retinopathy, and Alzheimer’s diseases [12]. Here, in this study, we also evaluated pericyte status by $\alpha$-SMA staining. No obvious perivascular cytopathology was observed in the cases we studied.

Patients with neurodegeneration disease often have damage in the white matter, which is composed of axonal fibers interconnecting neurons in the brain [22]. White matter damage, which includes demyelination and inflammation, is associated with cognitive dysfunction and is one of the most important factors in the complex etiology of AD [23, 24]. Our study suggests that chronic activation of astrocytes and microglia may contribute to myelin sheath loss and nerve fiber degeneration. Abnormal tau was highly expressed in AD compared to PD and NC. Neurofibrillary tangles deposition is independent of plaques formation in the course of AD. No dysfunctional pericytes were observed in AD, PD and NC cases. Taken together, reactive astrocytes may produce toxic effects on myelin sheath and abnormal tau has a better correlation with AD dementia than amyloid beta.

Data Availability

The data we used are from quantification analysis from VISIOPHARM imaging analytic software. All these data used to support the findings of this study are included within the article and can be shared to anyone.

Conflicts of Interest

The authors have no conflicts of interest.

Authors’ Contributions

JX, YW, and TSLB were involved in study concept and design. FH and JX were responsible for IHC and qualitative analysis of data. FH and JX assisted in statistical analysis and interpretation. FH, QW, RJP, and JSP were involved in preparation of tissue. JX, JCM, YW, and TSLB obtained funding. FH, JX, JSP, and TSLB carried out drafting of the manuscript. JX and FH assisted in preparation of figures/tables. QW, JCM, and JSP were responsible for critical revision of the manuscript for important intellectual content. JX, YW, and TSLB performed study supervision.
Acknowledgments
The authors thank Ms. Erin E. Franklin and Mr. Michael Baxter of the Knight Alzheimer Disease Research Center Neuropathology Core at Washington University School of Medicine, for coordination of the tissue preparation and expert technical assistance. We also thank Mr. William Knight for editorial assistance. This research was funded by the Bright Focus Foundation, NIH, (R01 NS092865, R01 AG052550, P01 AG03991, and P50 AG05681).

References
[1] M. Bozzali, A. Falini, M. Franceschi et al., “White matter damage in Alzheimer’s disease assessed in vivo using diffusion tensor magnetic resonance imaging,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 72, no. 6, pp. 742–746, 2002.
[2] J. Jackson, G. Bianco, A. O. Rosa et al., “White matter tauopathy: transient functional loss and novel myelin remodelling,” Glia, vol. 66, no. 4, pp. 813–827, 2018.
[3] G. Mancardi, B. Hart, L. Roccatagliata et al., “Demyelination and axonal damage in a non-human primate model of multiple sclerosis,” Journal of the Neurological Sciences, vol. 184, no. 1, pp. 41–49, 2001.
[4] B. E. Grueter and U. G. Schulz, “Age-related cerebral white matter disease (leukoaraiosis): a review,” Postgraduate Medical Journal, vol. 88, no. 1036, pp. 79–87, 2012.
[5] O. R. Phillips, K. A. Clark, E. Luders et al., “Superficial white matter: effects of age, sex, and hemisphere,” Brain Connectivity, vol. 3, no. 2, pp. 146–159, 2013.
[6] M. Wu, L. H. Lu, A. Lowes et al., “Development of superficial white matter and its structural interplay with cortical gray matter in children and adolescents,” Human Brain Mapping, vol. 35, no. 6, pp. 2806–2816, 2014.
[7] O. R. Phillips, S. H. Joshi, F. Squitieri et al., “Major superficial white matter abnormalities in huntington’s disease,” Frontiers in Neuroscience, vol. 10, no. 197, 2016.
[8] M. Noble, K. Murray, P. Stroobant, M. D. Waterfield, and P. Riddle, “Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell,” Nature, vol. 333, no. 6173, pp. 560–562, 1988.
[9] W. Liedtke, W. Edelmann, P. L. Bieri et al., “GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination,” Neuron, vol. 17, no. 4, pp. 607–615, 1996.
[10] S. C. Barnett and C. Linnington, “Myelination,” The Neuroscientist, vol. 19, no. 5, pp. 442–450, 2013.
[11] J. den Haan, T. H. J. Morrema, P. D. Verbraak et al., “Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas,” Acta Neuropathologica Communications, vol. 6, no. 1, p. 147, 2018.
[12] G. Allt and J. G. Lawrenson, “Pericytes: cell biology and pathology,” Cells Tissues Organs, vol. 169, no. 1, pp. 1–11, 2001.
[13] H. Braak, K. D. Tredici, U. Büth, R. A. I. de Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson’s disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003.
[14] H. Braak and E. Braak, “Neuropathological staging of Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no. 4, pp. 239–259, 1991.
[15] H. Braak, I. Alafuzoff, T. Arzberger, H. Kretzschmar, and K. Del Tredici, “Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry,” Acta Neuropathologica, vol. 112, no. 4, pp. 389–404, 2006.
[16] J. Xu, J. Sun, R. J. Ferrin et al., “Translocator protein in late stage Alzheimer’s disease and dementia with lewy bodies brains,” Annals of Clinical and Translational Neurology, 2019.
[17] S. T. Brady, A. S. Witt, L. L. Kirkpatrick et al., “Formation of compact myelin is required for maturation of the axonal cytoskeleton,” Journal of Neuroscience, vol. 19, no. 17, pp. 7278–7288, 1999.
[18] A. Meyer-Franke, S. L. Shen, and B. A. Barres, “Astrocytes induce oligodendrocyte processes to align with and adhere to axons,” Molecular and Cellular Neuroscience, vol. 14, no. 4-5, pp. 385–397, 1999.
[19] H. Andrews, K. White, C. Thomson et al., “Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse,” Journal of Neuroscience Research, vol. 83, no. 8, pp. 1533–1539, 2006.
[20] K.-A. Nave, “Myelination and support of axonal integrity by glia,” Nature, vol. 468, no. 7321, pp. 244–252, 2010.
[21] E. E. Congdon and E. M. Sigurdsson, “Tau-targeting therapies for Alzheimer disease,” Nature Reviews Neurology, vol. 14, no. 7, pp. 399–415, 2018.
[22] L. Pini, M. Pievani, M. Bocchetta et al., “Brain atrophy in Alzheimer’s disease and aging,” Ageing Research Reviews, vol. 30, pp. 25–48, 2016.
[23] H. Tomimoto, “White matter integrity and cognitive dysfunction: Radiological and neuropsychological correlations,” Geriatrics & Gerontology International, vol. 15, no. 1, pp. 3–9, 2013.
[24] J.-Q. Li, L. Tan, H.-F. Wang et al., “Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, no. 5, pp. 476–484, 2016.